$ATEC

Marshall Tyson Eliot sold $79K of ATEC

Marshall Tyson Eliot (GENERAL COUNSEL & CORP. SEC.) sold 8,168 shares of Alphatec Holdings, Inc. (ATEC) at $9.65 on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Marshall Tyson Eliot
Published Aug 8, 2026, 12:25 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 12:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEC
Neutral
high confidence
Mentioned
$ATEC
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATECNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity but does not include any new company fundamentals, guidance, or regulatory/operational developments.

02

Market read

Traders may treat this as low-signal sentiment information rather than a catalyst.

03

What to watch

The article does not state whether the sale was part of a larger series, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: Form 4 filed 2026-08-07 for a sale executed 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Alphatec Holdings, Inc.

Company-level read

Ticker impact

$ATECNeutralHigh confidence
Context

Alphatec Holdings insider Marshall Tyson Eliot filed a Form 4 selling 8,168 shares at $9.65 on 2026-08-05 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing specifies an open-market sale under a pre-arranged Rule 10b5-1 plan, with no accompanying company news, contract, or guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even planned 10b5-1 sales can coincide with insider expectations of near-term risk, so traders may still watch for follow-on selling or other filings.

Key entities

  • Alphatec Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Marshall Tyson Eliot

    General Counsel and corporate SEC officer who sold shares under a 10b5-1 plan.

Related articles

$ATECMed

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.

$ATECMed

Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB

$ATECMedAI 8/10

Here is Why Alphatec (ATEC) is One of the Best Cheap Stocks Under $10 to Buy in June

Alphatec Holdings (ATEC) reported Q1 2026 results on May 5, with total revenue up 14% to $192 million and surgical revenue up 17%. The company posted non-GAAP adjusted EBITDA of $21 million and said a new bank facility would cut annual interest expense by over $6 million and extend maturities to 2031. For 2026, it expects revenue of about $882 million and adjusted EBITDA of about $134 million.

$ATECMed

Alphatec Holdings, Inc. (ATEC): 12 Best Future Stocks to Buy Right Now.

Alphatec Holdings (ATEC) saw two analyst price-target cuts on May 7 while ratings stayed Overweight. Barclays lowered its target to $24 from $27, citing confidence in long-term growth despite near-term operational issues. Piper Sandler cut its target to $14 from $25 after first-quarter results missed expectations due to a weak EOS quarter and softer revenue per case from product mix headwinds.